The Treatment of Bipolar Depression: Current Status and Future Perspectives by Jelen, Luke & Young, Allan
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1007/s40473-020-00200-x
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Jelen, L., & Young, A. (2020). The Treatment of Bipolar Depression: Current Status and Future Perspectives.
Current Behavioral Neuroscience Reports. https://doi.org/10.1007/s40473-020-00200-x
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
BIPOLAR DISORDER (J SOARES AND M SANCHES, SECTION EDITORS)
The Treatment of Bipolar Depression: Current Status
and Future Perspectives
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Abstract
Purpose of Review This paper aims to review current available treatment options and to consider future directions in the treatment
of bipolar depression.
Recent Findings There are a limited number of established treatments that have demonstrated varied efficacy in acute bipolar
depression including modern antipsychotics (quetiapine, lurasidone, olanzapine ± fluoxetine and recently cariprazine) and mood
stabilisers (lamotrigine and valproate). Lithium has a role in protecting against depressive relapses and suicide. Alternative and
experimental treatments including pramipexole, modafinil/armodafinil, omega-3 fatty acids and thyroxine may be used to
augment the treatment of bipolar depression. Ketamine represents a major breakthrough, producing rapid reductions in depres-
sive symptoms even in cases of treatment-resistance, but challenges remain in how best to maintain response and reduce
unwanted side effects.
Summary There remains uncertainty with regard to the relative efficacy and safety of established and experimental treatments for
bipolar depression. Further work using consistent, optimal trial designs as well as further investigation into novel compounds and
treatment interventions is warranted.
Keywords Bipolar disorder . Bipolar depression . Antidepressants . Mood stabilisers . Antipsychotics . Experimental treatments
Introduction
Bipolar disorder is a disabling condition characterised by re-
current episodes of depression and mood elevation (mania or
hypomania) and mixed states. With respect to symptom dura-
tion, depression is typically the predominant phase in bipolar
disorder [1], accounting for a greater proportion of impaired
social and occupational functioning, morbidity and an excess
mortality associated with suicide [2, 3].
Bipolar depression poses a therapeutic challenge, com-
plicated by the need to relieve depressive symptoms with-
out precipitating mania, hypomania or worsening cycle
frequency [4]. Despite its high prevalence and clinical im-
portance, until recently there have been relatively few
randomised controlled trials (RCTs) in bipolar depression.
Although there are a limited number of established treat-
ments demonstrating efficacy in acute episodes, there is a
paucity of evidence to decide between different agents and
the therapeutic, prophylactic or harmful effects in the long
term are less well evaluated.
Bipolar I and II are themost commonly diagnosed subtypes
of bipolar disorder. For a diagnosis of bipolar I, criteria must
have been met for at least one manic episode which may have
been preceded and may be followed by major depressive ep-
isodes. To qualify for a diagnosis of bipolar II, the individual
must have had at least one hypomanic and at least one major
depressive episode [5]. Relative to bipolar I, there has been
less research on the safety and efficacy of pharmacological
treatments in bipolar II disorder and specifically bipolar II
depression [6]. Only a limited number of agents have been
examined in both.
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Here, we first review current evidence for recognised treat-
ments in bipolar depression before exploring alternative and
experimental treatment options. Finally, we summarise our
findings and discuss limitations in this field of research before
considering future perspectives in the treatment of bipolar
depression.
Antidepressants
Although antidepressants are commonly prescribed for bipo-
lar depression, their use remains controversial [7]. There is a
particular lack of placebo-controlled, monotherapy trials ex-
amining efficacy of antidepressants in bipolar depression with
notable concerns regarding the risk of mood activation, caus-
ing a switch to mania or inducing rapid cycling, with the use
of ‘unopposed’ antidepressants (i.e. without mood stabiliser or
antipsychotic protection).
Two large placebo-controlled trials provided evidence to
suggest a potential lack of efficacy of antidepressants in the
treatment of bipolar depression. The first, an add-on study,
found no additional benefit from adjunctive paroxetine or
bupropion as compared with optimised mood stabiliser or
antipsychotic treatment [8]. The second, the EMBOLDEN-II
study, compared the efficacy of quetiapine with placebo, in-
cluding paroxetine as a comparator [9]. Although quetiapine
was found to be superior to placebo for treating acute depres-
sive episodes in bipolar I and II disorder, paroxetine was not.
Findings from meta-analyses regarding the efficacy of an-
tidepressants have been conflicting. While one found no ad-
vantage of antidepressants over placebo [10], three others
have suggested greater efficacy of antidepressants compared
with placebo in acute bipolar depression [11–13]. In a double-
blind comparison trial of venlafaxine versus lithium mono-
therapy, venlafaxine had significantly greater response and
remission rates, without an increase in hypomanic symptoms
in bipolar II depression [14]. A further follow-up study of
bipolar II patients in remission from a depressive episode
demonstrated a lower relapse rate for fluoxetine compared
with lithium or placebo, again without an increase in hypo-
manic symptoms [15].
The frequency and severity of antidepressant-associated
mood elevations are significantly higher in bipolar I patients
compared with bipolar II [16]. A large naturalistic study found
antidepressant monotherapy to be associated with an in-
creased risk of mania in bipolar I patients, while in those also
receiving a mood stabiliser, this higher risk was not seen [17].
The risk seems particularly increased with tricyclic-
antidepressants (TCAs) and the serotonin-norepinephrine re-
uptake inhibitor (SNRI) venlafaxine compared with selective
serotonin reuptake inhibitors (SSRIs) [11, 18].
While there may be a role for the cautious use of antide-
pressant monotherapy in select bipolar II patients who have
previously demonstrated a favourable response, monitoring
closely for any adverse reactions such as hypomania or agita-
tion, there is an overall consensus that, especially in bipolar I
patients, antidepressants should only be prescribed in combi-
nation with antimanic or antipsychotic medications [7]. If an
antidepressant is to be prescribed, an SSRI or buproprion is
generally recomended, while TCAs are usually best avoided.
[19].
Mood Stabilisers
Lithium
The use of lithium in treating bipolar depression is supported
by a number of early small double-blind trials suggesting su-
periority of lithium compared with placebo; however, most of
these studies had methodological shortcomings [20]. In the
only modern, rigorously conducted RCT (EMBOLDEN I),
although quetiapine demonstrated superiority over placebo
in the treatment of acute bipolar depression, lithiummonother-
apy did not significantly differ from placebo in reducing de-
pressive symptom scores [21]. It should be noted, in this trial,
median serum lithium levels were at the lower end of target
range (0.6 mEq/L) and 35% of patients had serum concentra-
tions below this level. Indeed, higher serum levels may be
required for sufficient antidepressant effects, but this comes
with an increased risk of adverse reactions. Nonetheless, there
is evidence that lithium prevents depressive relapse, albeit
with more robust protective effects on manic relapse [22,
23], and has an important role in reducing suicide risk in
bipolar disorder patients [24].
Lamotrigine
Initial findings from five trials investigating the efficacy of
lamotrigine in acute bipolar I and II depression were essen-
tially negative in regard to the primary outcome [25]; howev-
er, a subsequent meta-analysis, which pooled data from these
trials, determined a modest beneficial effect of lamotrigine on
depressive symptoms [26]. Further analysis showed a more
substantial effect in those patients with a baseline Hamilton
Rating Scale for Depression (HAM-D) score of 24 and above,
while in patients with scores below 24 at entry, the high pla-
cebo response likely prevented detection of an effect of
lamotrigine in individual studies. Add-on studies have shown
additional benefits of combining lamotrigine with lithium [27]
and with quetiapine [28] treatment in bipolar depression.
Lamotrigine is approved by the FDA as a maintenance
treatment in bipolar disorder with evidence for effectiveness
in protecting against depressive and manic relapses with more
robust effects against depression [29]. Although it may be
used in acute bipolar depression, a practical consideration
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which may limit clinical utility is the need for cautious dose
titration to avoid potential dermatological complications.
Valproate
There are a limited number of small studies of valproate in
bipolar depression which have been summarised in two meta-
analyses [30, 31]. Taken together, these provide some evi-
dence to support efficacy of valproate monotherapy in bipolar
depression although a larger study would be helpful if it con-
firmed these putative acute benefits. There is also limited ev-
idence to suggest that valproate protects against depressive
relapse when used as a maintenance treatment [32], but again
this is based on a small number of participants. The
BALANCE trial compared valproate, lithium and their com-
bination in a randomised open-label relapse prevention trial
[23]. Trial findings demonstrated lithium monotherapy and
lithium in combination with valproate were superior to
valproate alone in preventing both manic and depressive re-
lapses. Naturally, patients and clinicians need to consider ac-
ceptability and potential side-effect burden when deciding be-
tween lithium, valproate or their combination as longer term
treatments in bipolar disorder.
Carbamazepine
The evidence base concerning the treatment of bipolar de-
pression with carbamazepine is poor. A few early trials
exist; however, most are uncontrolled and open label with
small numbers of subjects. In one RCT comparing treat-
ment with placebo versus carbamazepine for 12 weeks,
although carbamazepine failed to significantly differentiate
from placebo in depressive symptom measures at most
post-baseline measure points, there was a higher clinical
response rate at endpoint compared with placebo (30/
47 = 63.8% vs. 8/23 = 34.8%, p = 0.044) [33]. In a
Cochrane review of oxcarbazepine, a keto derivative of
carbamazepine, as an adjunctive to lithium, oxcarbazepine
reduced depression rating scale scores more than carba-
mazepine in a group of manic participants [34]. However,
the role of this agent in bipolar depression remains poorly
investigated.
Antipsychotics
Several second-generation antipsychotic medications have
demonstrated effectiveness in treating bipolar depression.
However, efficacy cannot be supported for the class as a whole
with evidence instead suggesting a role for specific agents.
Notably, these include quetiapine, olanzapine, lurasidone
and most recently cariprazine.
Quetiapine
A number of trials have found quetiapine to be effective both
as a short-term treatment and for relapse prevention in bipolar
depression. Two initial RCTs demonstrated acute effective-
ness of quetiapine at doses of 300 mg and 600 mg in bipolar
I and II depression as early as week one [35, 36]. In two
subsequent RCTs exploring the efficacy and tolerability of
quetiapine and active comparators lithium and paroxetine,
quetiapine again outperformed placebo in attenuating depres-
sive symptoms while the active comparators did not [9, 21].
Placebo-controlled studies of quetiapine extended release
(XR) monotherapy have also consistently demonstrated effi-
cacy in bipolar depression [37–39]. In terms of relapse pre-
vention, in patients with bipolar I disorder previously
stabilised on quetiapine, continued maintenance therapy with
quetiapine significantly increases time to recurrence of depres-
sive or manic relapse compared with placebo [40], regardless
of any combination with lithium or valproate [41]. Although
effective in bipolar depression, quetiapine may not always be
tolerated, particularly with regard to adverse effects including
excess sedation, somnolence and weight gain [42].
Olanzapine ± Fluoxetine
Olanzapine monotherapy has shown superior benefits to pla-
cebo in the treatment of bipolar depression with a modest
antidepressant effect [43–45]. In a subpopulation analysis of
Japanese patients, there was a greater benefit on bipolar de-
pression scores [46]. There is additional evidence to support a
prophylactic effect as olanzapine delays relapse into subse-
quent mood episodes compared with placebo in bipolar disor-
der patients who have already responded to olanzapine for a
manic or mixed episode [47].
In the original RCT, the combination of olanzapine
with fluoxetine separated further from placebo than
olanzapine monotherapy [43] and the efficacy of this
combination has been further supported by findings from
comparison studies [48–50]. Compared with lamotrigine,
in patients with bipolar I depression, those receiving
olanzapine + fluoxetine had significantly greater im-
provement in depressive symptoms at week 7 and week
25 time points [48, 50]. However, olanzapine + fluoxe-
tine treatment was associated with significantly greater
rates of side effects including somnolence, increased ap-
petite, dry mouth, sedation, weight gain and tremor.
Additionally, in olanzapine + fluoxetine-treated patients,
weight, total cholesterol and triglyceride levels were all
significantly elevated compared with those treated with
lamotrigine. This suggests that although olanzapine + flu-
oxetine may be more effective in bipolar depression;
lamotrigine shows better tolerability.
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Lurasidone
Evidence to support efficacy of lurasidone in the treatment of
bipolar depression comes from three large placebo-controlled
studies [51–53]. In the first, comparing lurasidone monothera-
py versus placebo in bipolar I depression over a 6-week period,
lurasidone significantly reduced depressive symptoms com-
pared with placebo [51]. Two further placebo-controlled trials
showed significant benefits of lurasidone when used as an
adjunct to lithium or valproate in improving depressive symp-
toms in bipolar depression [52, 53]. It is worth mentioning a
final RCTof lurasidone in major depressive disorder with sub-
threshold hypomanic symptoms (mixed features) showed that
lurasidone was also effective in reducing depressive symptoms
and overall illness severity in this patient group [54].
Overall, lurasidone seems better tolerated than other anti-
psychotic medications but notable adverse events include
akathisia, somnolence, extrapyramidal symptoms and nausea.
Importantly lurasidone produces minimal changes in weight,
lipids and measures of glycaemic control [51–53]. When
balancing benefits and harms of potential treatment options,
although lurasidone may not be quite as efficacious as
quetiapine or olanzapine + fluoxetine, it would appear to dem-
onstrate an enhanced tolerability profile, increasing its overall
utility [55].
Cariprazine
Cariprazine is a novel antipsychotic that is a selective dopa-
mine D3 and D2 partial agonist with higher affinity for the D3
versus D2 receptor [56]. An initial 8-week phase IIB study of
cariprazine at a dose of 1.5 mg/day demonstrated consistent
efficacy compared with placebo in bipolar I depression and
was generally well tolerated [57]. A larger phase III study
demonstrated that cariprazine at both 1.5 mg/day and
3.0 mg/day was significantly more effective than placebo in
improving depressive symptoms in bipolar I depression [58•].
Common adverse events in participants receiving cariprazine
were nausea, akathisia, dizziness and sedation while mean
changes in weight and metabolic parameters were relatively
small and comparable across treatment groups. The use of
cariprazine in the treatment of depressive episodes associated
with bipolar I disorder has since been approved by the FDA.
Others (Aripiprazole and Ziprasidone)
There is limited evidence from open-label studies to suggest
benefits of aripiprazole in bipolar depression as an add-on
treatment [59, 60]. However, in two identically designed, 8-
week, RCTs of aripiprazole monotherapy in bipolar depres-
sion, although significant differences in depressive symptoms
were seen during weeks 1–6, aripiprazole did not significantly
separate from placebo at week 8 (the primary end point) [61].
Similar to aripiprazole, there are two negative RCTs of
ziprasidone in the treatment of bipolar depression [62].
Furthermore, in another large study examining efficacy of
adjunctive ziprasidone to pre-existing mood stabiliser in acute
bipolar depression, adjunctive ziprasidone treatment failed to
separate from mood stabiliser alone in depression ratings at
6 weeks [63].
Taken together, these findings suggest aripiprazole and
ziprasidone monotherapy are probably not effective in bipolar
depression and should not be used routinely [64].
Alternative and Experimental Treatments
Pramipexole
With study findings supporting efficacy of cariprazine in bi-
polar depression, dopamine agonism/partial agonism has been
suggested as a potential mechanism for antidepressant action
[65•]. Pramipexole is a dopamine D2/D3 agonist commonly
used in the management of Parkinson’s disease. There have
been two small RCTs of pramipexole combined with existing
mood stabiliser treatment both suggesting efficacy and toler-
ability in bipolar depression [66, 67]. Neither study detected
an increased risk of switching to mania/hypomania in the
pramipexole-treated groups; however, these are small studies
and the data are not sufficient to exclude this potential risk.
Modafinil and Armodafinil
The wakefulness-promoting agent modafinil and its longer
lasting R-enantiomer (armodafinil) both act to inhibit
dopamine-reuptake and have a potential adjunctive role in
bipolar depression [68]. One placebo-controlled trial examin-
ing adjunctive modafinil at doses of 100 mg–200 mg/day in
bipolar depression found significantly greater improvement in
depressive symptoms in the modafinil group at week 2, main-
tained through to week 6 [69]. A phase II and subsequent
phase III study of adjunctive armodafinil 150 mg/day in bipo-
lar I depression again demonstrated significantly improved
depressive symptoms compared with placebo and was gener-
ally well tolerated [70, 71]. However, in two further double-
blind RCTs of adjunctive armodafinil in bipolar I depression,
although armodafinil reduced depressive symptoms to a great-
er extent than placebo, it did not separate from placebo in the
primary efficacy outcomes in either study [72, 73]. A recent
meta-analysis combining these studies found that compared
with placebo, augmentation with modafinil or armodafinil
was associated with significantly greater treatment response
and remission, encouraging further studies that delineate sub-
types of bipolar depression responsive to these novel dopa-
mine enhancing agents [68].
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Ketamine
There is growing interest in the potential of ketamine, an un-
competitive N-Methyl-D-Aspartate (NMDA) receptor antago-
nist, for the treatment of unipolar and bipolar depression.
Rapid reductions in depressive symptoms have been reliably
demonstrated following a single subanaesthetic ketamine infu-
sion, including in cases of treatment-resistance [74]. Although
not fully understood, ketamine’s mechanism of antidepressant
action is thought to be mediated through NMDA receptor an-
tagonism, resulting in increased cortical glutamate, increased
α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid
(AMPA) signalling and downstream effects on synaptogenic
and neuroplastic pathways. [75].
In a randomised, placebo-controlled, double-blind, cross-
over add-on study of 18 patients with treatment-resistant bi-
polar depression already receiving lithium or valproate, fol-
lowing a single ketamine infusion (0.5 mg/kg over 40 min)
depressive symptoms significantly improved within 40 min
compared with placebo and remained significant through
day 3 [76]. There was an impressive response rate with 71%
of subjects showing a response to ketamine compared with
only 6% for placebo. These findings have been replicated in
a similarly designed study of 15 patients with treatment-
resistant bipolar depression (maintained on lithium or
valproate), which demonstrated a comparable rapid and robust
antidepressant response following a single ketamine infusion,
alongside a significant improvement in suicidal ideation [77].
The most common side effect was acute dissociative symp-
toms; otherwise, ketamine was generally well tolerated.
Although ketamine may offer a rapid antidepressant effect
in cases of bipolar depression, unfortunately the effect is not
sustained in the long term. While one option is repeated keta-
mine infusions [78], the feasibility, accessibility and resources
required can limit availability and other routes of administra-
tion (oral, sublingual, intranasal, intramuscular, subcutaneous)
could prove preferred alternatives for repeat administrations
[79]. However, comparatively fewer studies have fully evalu-
ated these alternative routes and further investigation is
warranted.
An intranasal formulation of ketamine’s (S)-enantiomer,
esketamine, was recently approved by the FDA for unipolar
depression. Although no trials have specifically examined the
use of this formulation in bipolar depression, it could be a
potential avenue to consider and explore in the future.
Memantine
Memantine is a non-competitive NMDA antagonist that lacks
dissociative side effects associated with ketamine at therapeu-
tic doses and has also been investigated as an adjunctive treat-
ment in bipolar depression. Although results of one RCT sug-
gested an early antidepressant effect of memantine
augmentation to lamotrigine in bipolar depression, this effect
failed to separate from placebo at the 8-week trial endpoint
[80]. In an RCT examining effects of memantine augmenta-
tion to valproate in bipolar II depression, tumour necrosis
factor α levels (TNF-α) were significantly lower in the
memantine group, suggesting an anti-inflammatory effect,
but there was no significant advantage over placebo in terms
of antidepressant effect [81]. A meta-analysis of these trials
showed no significant benefit of memantine over placebo aug-
mentation in bipolar depression but advised there was not
enough evidence to draw meaningful conclusions [82].
Thyroxine/Levothyroxine
Thyroid abnormalities associated with bipolar disorder are a
significant problem that can lead to poor outcomes if not
recognised and treated [83]. The benefits of adjunctive treat-
ment with thyroid hormones at supraphysiologic doses have
been explored bipolar depression. In a placebo-controlled
study, the addition of levothyroxine to continuing treatment
with mood stabiliser and/or antidepressant medication in bi-
polar depression showed no significant benefit over placebo
[84]. Interestingly, a secondary analysis revealed a significant
difference in female patients only. More recently a double-
blind, placebo-controlled trial in 32 patients with treatment-
resistant rapid cycling bipolar disorder found that following
adjunctive levothyroxine treatment patients spent significantly
less time depressed or in a mixed state and greater time
euthymic (within groups) [85]. Between groups, those in the
levothyroxine group had a significantly greater increase in
time euthymic and decrease in time in the mixed state com-
pared with the placebo group.
Omega-3 Fatty Acids
There is limited evidence for the use of omega-3 fatty acids in
bipolar depression and findings of individual studies have not
been consistent. While one RCT examining the efficacy of
adjunctive ethyl-eicosapentaenoic acid (EPA) in bipolar de-
pression (1–2 g/day) found a significant improvement in
HAM-D scores compared with placebo [86], another RCT
found no significant difference between adjunctive EPA
(6 g/day) and placebo in changes from baseline depressive
symptoms [87]. A later meta-analysis, of 5 pooled datasets
(n = 291), revealed a significant effect in favour of adjunctive
omega-3 on the outcome of bipolar depression with a moder-
ate effect size but uncertainty remains regarding optimum for-
mulation and dosage [88].
Mifepristone
At high doses, the progesterone receptor antagonist mifepris-
tone is an antagonist of the glucocorticoid receptor (GR)
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subtype of corticosteroid receptor and preliminary evidence
demonstrated potential cognitive-enhancing and mood-
elevating properties in bipolar disorder [89]. However, in a
larger RCT examining adjunctive mifepristone (600 mg/day)
for 1 week in 60 patients with bipolar depression, although
treatment was well tolerated and a beneficial effect in spatial
working memory was demonstrated, there was no significant
effect of mifepristone on depressive symptoms [90]. The lack
of antidepressant effect may have been dose related as the
dose used would not be expected to reliably generate plasma
levels within a therapeutic range suggested by previous work
in psychotic depression [91].
Non-pharmacological
Although there are limited RCTs of electroconvulsive ther-
apy (ECT) in mania and bipolar depression, there is a wide
consensus that ECT is an effective treatment for both acute
mania and bipolar depression even in pharmacotherapy-
resistant patients [92]. In large sample of drug-resistant
bipolar depressed patients, at the end of an ECT course,
an antidepressant response was seen in 201 out of 295
individuals (68.1%) [93] and another trial suggests ECT
may be more effective than pharmacological treatment in
treatment-resistant bipolar depression [94].
Repetitive transcranial magnetic stimulation (rTMS) is a
non-invasive brain stimulation therapy. There is growing ev-
idence to support its use in bipolar depression with findings
from a meta-analysis suggesting rTMS to be a safe, effective
treatment option and does not appear to be associated with
treatment-emergent affective switches [95]. Efforts to develop
the technique are ongoing with encouraging results in bipolar
depression using a novel approach called ‘deep’ TMS or
(dTMS) to stimulate deeper brain regions [96].
Other non-invasive physical treatments focussing on sleep
disturbances and circadian rhythm dysfunction including
sleep deprivation, sleep phase advance and light therapy
may serve as potential add-on treatment options in bipolar
depression to accelerate and sustain antidepressant response
[97, 98].
Last, but by no means least, adjunctive psychotherapy has
an important role in terms of relapse prevention and episode
stabilisation in bipolar disorder [99]. Psychotherapy is an op-
portunity for psychoeducation and may help to identify and
monitor early signs of mood change, develop strategies for
relapse prevention, explore and manage relationship between
mood, stress and interpersonal difficulties, encourage medica-
tion adherence, establish regular sleep-wake cycles and ad-
dress substance misuse [100]. Although a discussion of differ-
ent psychotherapy modalities is beyond the scope of this re-
view, in terms of bipolar depression, cognitive behavioural
therapy (CBT), family therapy and psychoeducation may be
particularly useful in protecting against recurrences [99, 100].
Summary and Future Perspectives
A summary of established and alternative/experimental phar-
macological treatments in bipolar depression discussed in this
review is provided in Table 1. The development of guidance
and expert treatment recommendations for bipolar depression
has been largely informed by the strength of evidence for par-
ticular drugs or by direct comparative data [19]. However, as
shown in Table 2, treatment recommendations are not always
consistent, with large variation observed in terms of guideline
recommendations and interpretation of available evidence. As
one example, the 2017 International College of Neuro-
Psychopharmacology (CINP) treatment guidelines recom-
mend aripiprazole and imipramine monotherapy as third-line
strategies in bipolar depression [102•]. Uncertainty remains
with regard to the relative efficacy and safety of antidepres-
sants, mood stabilisers, antipsychotics and experimental treat-
ments for bipolar depression.
One attempt to address this issue has come from multiple-
treatment meta-analyses. In a large network meta-analysis of 29
studies including 8331 subjects, olanzapine + fluoxetine,
lurasidone, olanzapine, valproate, SSRIs and quetiapine ranked
highest for effect size and olanzapine + fluoxetine also ranked
highest for response [64]. A further meta-analysis of 24 trials
(7307 subjects) in bipolar depression found statistical superior-
ity over placebo for olanzapine + fluoxetine ≥ valproate >
quetiapine >lurasidone > olanzapine > aripiprazole and carba-
mazepine (in order of effect size) [104]. However, these meta-
analyses are limited by the small numbers of controlled trials of
bipolar depression treatments and by themethods used to assess
efficacy meaning certain studies cannot be included as param-
eters such as outcome and trial duration do not match and
cannot be reliably compared with others. This is particularly
relevant for early studies of lithium. Furthermore, these network
meta-analyses may not be stable as rankings are influenced by
inclusion criteria and indirect comparisons sometimes contra-
dict direct comparison findings [65•].
Mindful of these limitations and considering the available
evidence, quetiapine is likely the most efficacious established
treatment for bipolar depression. Other first-line agents to con-
sider include lurasidone, olanzapine ± fluoxetine, lamotrigine
and valproate. Cariprazine may become more widely used in
the future. Lithium is also probably effective in bipolar depres-
sion, but the supporting evidence is limited. Alternative treat-
ments including pramipexole, modafinil/armodafinil, omega-
3 fatty acids and thyroxine can be used to augment the treat-
ment of bipolar depression. In cases of treatment-resistance,
ketamine may provide rapid reductions in depressive symp-
toms, but challenges remain in considering the most appropri-
ate route of administration and how best to maintain response.
Although still highly stigmatised, ECT is another effective
treatment and should also be considered in cases of
treatment-resistance and high suicidal risk.
Curr Behav Neurosci Rep
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The rapid improvement in depressive symptoms occur-
ring with ketamine administration, taking place within
hours to days rather than weeks to months, represents a
paradigm shift in the treatment of depression and now the
ultimate goal is the development of rapid acting treatment
strategies with a prolonged antidepressant response. An
intranasal formulation of the (S)-enantiomer, esketamine,
has been developed with promising results following re-
peated administration in treatment-resistant unipolar de-
pression [105]. Although there have been no trials of in-
tranasal esketamine in bipolar depression completed to
date, work is now underway to determine safety and
efficacy of an inhaled esketamine formulation in bipolar
depression (ClinicalTrials.gov ID: NCT03965871).
Alternative and better tolerated ketamine-like agents that
affect glutamate neurotransmission may offer future prom-
ise in both unipolar and bipolar depression [106, 107]. The
psychedelic drug psilocybin, a 5-HT2A partial agonist, is
another compound with novel antidepressant mechanisms,
currently being investigated in unipolar major depressive
disorder (Cl inicalTria ls .gov ID: NCT03775200,
NCT03866174). While this may not be a suitable option
to explore in bipolar I depression, due to the potential risk
of mania, it may be an interesting avenue to explore in the
future in carefully selected bipolar II depressed individuals.
Other novel treatment strategies under investigation in
bipolar depression include adjunctive anti-inflammatory
agents and probiotics. Several proof-of-concept trials have
shown encouraging results for anti-inflammatory agents in
the treatment of bipolar depression with moderate effect
sizes and good tolerability [101, 103•, 108•]. Results from
trials of probiotics in bipolar depression are awaited
(ClinicalTrials.gov IDs: NCT02155972, NCT03349528).
Ideally large future studies, using stratified samples
enriched with individuals with immune dysfunction or
microbiome abnormalities, will establish the role of
adjunctive anti-inflammatory agents and probiotics in bi-
polar depression.
Conclusions
When deciding treatment options in bipolar depression, it is
important to balance to potential benefits and harms. The
treatments discussed in this review have substantial differ-
ences in terms of adverse effect profile, tolerability and accept-
ability. Considering each case individually and involving the
patient in their treatment planning are key.
Despite the severe clinical and socioeconomic impact,
research into the treatment of bipolar depression remains
limited. Further work using consistent, optimal trial de-
signs as well as further investigation into novel com-
pounds and treatment interventions is warranted.T
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Together this will widen the evidence-based treatment ar-
mamentarium in bipolar depression and allow more reli-
able treatment comparisons to be determined.
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